NASDAQ:SEPN - Nasdaq - US81734D1046 - Currency: USD
NASDAQ:SEPN (2/21/2025, 12:28:59 PM)
5.775
-0.11 (-1.95%)
The current stock price of SEPN is 5.775 USD. In the past month the price decreased by -69.61%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 68.5 | 845.42B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.62 | 392.37B | ||
JNJ | JOHNSON & JOHNSON | 16.2 | 389.70B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.59 | 230.48B | ||
MRK | MERCK & CO. INC. | 11.64 | 224.91B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.8 | 216.47B | ||
PFE | PFIZER INC | 8.36 | 147.37B | ||
SNY | SANOFI-ADR | 13.58 | 136.18B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.64 | 112.45B | ||
GSK | GSK PLC-SPON ADR | 7.76 | 74.25B | ||
ZTS | ZOETIS INC | 26.98 | 72.07B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.92 | 44.53B |
Septerna Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in South San Francisco, California and currently employs 68 full-time employees. The company went IPO on 2024-10-25. Septerna, Inc. is a clinical-stage biotechnology company. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. The company is focused in major therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
SEPTERNA INC
250 East Grand Avenue, Suite 65
South San Francisco CALIFORNIA US
Employees: 68
Company Website: https://septerna.com/
Phone: 16503383533
The current stock price of SEPN is 5.775 USD. The price decreased by -1.95% in the last trading session.
The exchange symbol of SEPTERNA INC is SEPN and it is listed on the Nasdaq exchange.
SEPN stock is listed on the Nasdaq exchange.
10 analysts have analysed SEPN and the average price target is 44.54 USD. This implies a price increase of 671.26% is expected in the next year compared to the current price of 5.775. Check the SEPTERNA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SEPTERNA INC (SEPN) has a market capitalization of 256.41M USD. This makes SEPN a Micro Cap stock.
SEPTERNA INC (SEPN) currently has 68 employees.
The Revenue of SEPTERNA INC (SEPN) is expected to grow by 406.62% in the next year. Check the estimates tab for more information on the SEPN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SEPN does not pay a dividend.
The PE ratio for SEPTERNA INC (SEPN) is 577.5. This is based on the reported non-GAAP earnings per share of 0.01 and the current share price of 5.775 USD. Check the full fundamental report for a full analysis of the valuation metrics for SEPN.
The outstanding short interest for SEPTERNA INC (SEPN) is 5.41% of its float. Check the ownership tab for more information on the SEPN short interest.
ChartMill assigns a fundamental rating of 4 / 10 to SEPN. No worries on liquidiy or solvency for SEPN as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months SEPN reported a non-GAAP Earnings per Share(EPS) of 0.01. The EPS increased by 102.05% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 375.5% | ||
ROA | 0.33% | ||
ROE | 0.41% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to SEPN. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -58693.33% and a revenue growth 406.62% for SEPN